{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:00:35Z","timestamp":1783472435870,"version":"3.55.0"},"reference-count":26,"publisher":"VM Media SP. zo.o VM Group SK","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologia i Neurochirurgia Polska"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.pjnns.2016.09.002","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T11:56:18Z","timestamp":1474631778000},"page":"101-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Yellow fever vaccine-associated neurotropic disease (YEL-AND) \u2013 A case report"],"prefix":"10.5603","volume":"51","author":[{"given":"Jolanta","family":"Florczak-Wyspia\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Nawotczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kozubski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3595","reference":[{"key":"10.1016\/j.pjnns.2016.09.002_bib0135","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention. Emerging Infections","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"July (RR07)","key":"10.1016\/j.pjnns.2016.09.002_bib0140","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.pjnns.2016.09.002_bib0145","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1586\/14760584.2013.836320","article-title":"Safety profile of the yellow fever vaccine Stamaril\u00ae: a 17-year review","volume":"12","author":"Cottin","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.pjnns.2016.09.002_bib0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/2051013613498954","article-title":"Advances and controversies in yellow fever vaccination","volume":"1","author":"Jonker","year":"2013","journal-title":"Ther Adv Vaccines"},{"issue":"June (1)","key":"10.1016\/j.pjnns.2016.09.002_bib0155","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune response during adverse events after 17D-derived yellow fever vaccination in Europe","volume":"197","author":"Bae","year":"2008","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.pjnns.2016.09.002_bib0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CVI.00078-07","article-title":"Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus","volume":"15","author":"Niedrig","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.pjnns.2016.09.002_bib0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.pjnns.2016.09.002_bib0170","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/cis520","article-title":"Vaccine administration decision making: the case of yellow fever vaccine","volume":"55","author":"Lown","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"48","key":"10.1016\/j.pjnns.2016.09.002_bib0175","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0180","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","article-title":"Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases","volume":"25","author":"McMahon","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0185","first-page":"269","volume":"88","author":"World Health Organization","year":"2013"},{"issue":"4","key":"10.1016\/j.pjnns.2016.09.002_bib0190","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1503\/cmaj.100619","article-title":"Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk","volume":"183","author":"Kuhn","year":"2011","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0195","series-title":"Report of CIOMS Working Group V. Appendix 5. List of Adverse Event\/Reaction Terms to be Considered Always \u201cSerious\u201d: Explanation. Geneva 2001","author":"WHO","year":"2001"},{"issue":"1","key":"10.1016\/j.pjnns.2016.09.002_bib0200","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1128\/CVI.00369-09","article-title":"Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination","volume":"17","author":"Silva","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0205","first-page":"319","article-title":"Efficacy and safety of vaccination against yellow fever of persons travelling to endemic areas","volume":"64","author":"D\u0105browska","year":"2010","journal-title":"Przegl Epidemiol"},{"issue":"6","key":"10.1016\/j.pjnns.2016.09.002_bib0210","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4269\/ajtmh.2009.09-0295","article-title":"Short report: incidence of yellow fever vaccine-associated neurotropic disease","volume":"81","author":"Guimard","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"49","key":"10.1016\/j.pjnns.2016.09.002_bib0215","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1016\/j.vaccine.2014.05.003","article-title":"Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil","volume":"32","author":"De Menezes Martins","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0220","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.pjnns.2016.09.002_bib0225","doi-asserted-by":"crossref","first-page":"e36291","DOI":"10.1371\/journal.pone.0036291","article-title":"First international external quality assessment study on molecular and serological methods for yellow fever diagnosis","volume":"7","author":"Domingo","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.pjnns.2016.09.002_bib0230","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/hv.22714","article-title":"Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more","volume":"9","author":"Miyaji","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trstmh.2006.04.001","article-title":"Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998\u20132002","volume":"101","author":"Tuboi","year":"2007","journal-title":"Trans R Soc Trop Med"},{"issue":"12","key":"10.1016\/j.pjnns.2016.09.002_bib0240","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viremia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0245","first-page":"34","article-title":"Transfusion \u2013 related transmission of yellow fever vaccine virus: California, 2009","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"30","key":"10.1016\/j.pjnns.2016.09.002_bib0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/157488611797579258","article-title":"Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review","volume":"6","author":"Thomas","year":"2011","journal-title":"Curr Drug Saf"},{"issue":"28","key":"10.1016\/j.pjnns.2016.09.002_bib0255","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.pjnns.2016.09.002_bib0260","series-title":"Infectious diseases related to travel, Chapter 3 \u2013 Viral hemorrhagic fevers","article-title":"Yellow fever","author":"Gershman","year":"2010"}],"container-title":["Neurologia i Neurochirurgia Polska"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002838431630113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002838431630113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T10:41:27Z","timestamp":1546944087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002838431630113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S002838431630113X"],"URL":"https:\/\/doi.org\/10.1016\/j.pjnns.2016.09.002","relation":{},"ISSN":["0028-3843"],"issn-type":[{"value":"0028-3843","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yellow fever vaccine-associated neurotropic disease (YEL-AND) \u2013 A case report","name":"articletitle","label":"Article Title"},{"value":"Neurologia i Neurochirurgia Polska","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pjnns.2016.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}